Aducanumab – hope in the fight against oblivion

This cryptic name stands for a very promising monoclonal antibody for the therapy of Alzheimer’s disease. Initial studies in mice and on patients have shown that the time- and dose-dependent administration of max. 10 mg (kg body weight of the antibody could lower the concentration of the probable causative ß-amyloids and also slow the progress of the disease. If the upcoming phase III studies are successful, two birds are killed with one stone:

1. the ß-amyloid hypothesis is confirmed and
2. we finally have a very promising therapeutic option.

I keep my fingers crossed for the researchers involved. For all of us…

Leave a Reply